Mediacom Communications Introduces Groundbreaking WiFi Experience with eero 7
BUSINESS WIRE)-- Mediacom Communications today announced the launch of Advanced WiFi powered by eero 7. This next-gen connectivity experience features a dual-band mesh WiFi 7 router developed by eero, an Amazon company, that offers enhanced coverage, faster speeds and added security while supporting many connected devices.
'We are thrilled to be the first U.S. broadband provider to make eero 7 available to our customers across our 22 states,' said Tapan Dandnaik, Mediacom's SVP, Operations, Product Strategy and Consumer Experience. 'With the capability to support 120 plus devices and coverage of up to 2,000 square feet per device, our groundbreaking Advanced WiFi powered by eero 7, which includes security, back-up and content protection, will help customers future-proof their home network while taking full advantage of the multi-gig and symmetrical speeds we are rolling out in our markets.'
Featuring eero's innovative TrueMesh networking technology, Advanced WiFi powered by eero 7 proactively searches for the optimal and most reliable WiFi connection possible. The technology also minimizes network disruptions to help eliminate dead spots and ensure fast and reliable WiFi availability in every room of the home.
Advanced WiFi powered by eero 7 also provides world-class encryption on every device, security protocols and ongoing security updates to help ensure the home network stays safe and secure.
'Our goal is to deliver fast, reliable, and secure wifi to customers around the world. That's why we're excited to work with Mediacom to deliver an exceptional wifi experience with eero 7 to their customers across 22 states,' said Nick Weaver, CEO and co-founder of eero. 'eero 7 supports multi-gigabit speeds and its compact form factor is packed with our innovative technologies, like TrueMesh, TrueRoam, and TrueChannel. It's the perfect router for customers who rely on their wifi for everyday internet activities, like streaming, studying, and working, and are looking to upgrade to the latest Wi-Fi 7 standard. We can't wait for Mediacom customers to experience eero 7.'
Advanced WiFi powered by eero 7 will be made available to all existing Mediacom Customers on May 6 th. 'Working with eero to deliver WiFi 7 technology is part of our ongoing commitment to bring cutting-edge connectivity to the communities we serve,' Dandnaik explained. 'As the number of connected devices in homes continues to grow, this solution delivers the bandwidth and power needed to keep everything running at peak performance.'
ABOUT MEDIACOM COMMUNICATIONS CORPORATION
Mediacom Communications Corporation is the 5th largest cable operator in the United States and the leading gigabit broadband provider to smaller markets primarily in the Midwest and Southeast. Through its fiber-rich network, Mediacom offers high-speed data, video, phone, and mobile services to over 3 million households and businesses across 22 states. The company delivers scalable broadband solutions to commercial and public-sector customers of all sizes through Mediacom Business and sells advertising and production services under the OnMedia brand. More information about Mediacom is available at mediacomcable.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
Hagens Berman Responds to Appeals to NCAA College Athlete Name, Image and Likeness Settlement
OAKLAND, Calif.--(BUSINESS WIRE)--Following the federal court's final approval to a historic $20 billion plus settlement with the NCAA allowing payments and benefits to college athletes for the use of their name, image and likeness (NIL), Hagens Berman responded to the first appeal. 'If these lawyers believe that a Title IX case will succeed, they should bring it and not hijack payments to college athletes that could be lifechanging.' To address questions from NCAA athletes about the impact of the appeal, Hagens Berman issued the following statement: 'Attorneys John Clune and Ashlyn Hare of Hutchinson Black and Cook LLC and Rebecca Peterson-Fisher of Katz Banks Kumin LLP have filed a notice of their intent to appeal the historic NCAA settlement approved June 6, 2025, by Judge Claudia Wilken. 'This appeal will block payments to hundreds of thousands of athletes, delaying payments by a minimum of several months to potentially a year or more. These attorneys are pursuing an appeal based on a Title IX issue that Judge Wilken already disposed of correctly, quickly and multiple times. 'Judge Wilken noted that these attorneys cited 'no authority that Title IX applies to damages awards distributions or that damages distributions made by a claims administrator are subject to Title IX.'' 'This is an antitrust case about competition, it is not a Title IX case, and now hundreds of thousands of athletes will have to wait to recover for past wrongs that were addressed in this lawsuit in order for these attorneys to take on this unrelated issue,' added Hagens Berman co-founder and managing partner, Steve Berman, who serves as court-appointed co-lead counsel. 'If these lawyers believe that a Title IX case will succeed, they should bring it and not hijack payments to college athletes that could be lifechanging.' Straight from the Bench In Judge Wilken's June 6, 2025, opinion on the order granting final approval to the settlement, the court clearly states that it overrules objections, noting, 'There is nothing in the SA [settlement agreement] that would prevent or prohibit schools from distributing benefits and compensation pursuant to the Injunctive Relief Settlement in a manner that complies with Title IX.' Berman added, 'Judge Wilken had made that same ruling earlier in the case, theoretically allowing objectors ample time to find authority to back up their objection, and they failed. It's a shame given this utter failure they will be holding up payments to athletes. I say shame on them.' Hagens Berman represents a class of nearly 400,000 college athletes in the lawsuit in which the total value under the new revenue-sharing model is expected to exceed $20 billion over the next 10 years. The settlement resolves three pending antitrust lawsuits, House v. NCAA, Hubbard v. NCAA, and Carter v. NCAA. Class members in the three affected cases may find out more about the claim process by visiting the settlement website at . Hagens Berman is a global plaintiffs' rights complex litigation law firm with a tenacious drive for achieving real results for those harmed by corporate negligence and fraud. Since its founding in 1993, the firm's determination has earned it numerous national accolades, awards and titles of 'Most Feared Plaintiff's Firm,' MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw.
Yahoo
38 minutes ago
- Yahoo
Establishment Labs Hosting Investor Day on June 12
NEW YORK, June 11, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at In-person attendance at the event is limited and requires advanced registration. Please email: ir@ for further information. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
43 minutes ago
- Business Wire
Establishment Labs Hosting Investor Day on June 12
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at In-person attendance at the event is limited and requires advanced registration. Please email: ir@ for further information. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at
